When do biologic drug patents expire and when will biosimilars launch?

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 4,931,110

Introduction

United States Patent 4,931,110 (hereafter “the ’110 patent”) pertains to a foundational patent in the pharmaceutical and chemical innovation landscape, pivotal for its claims related to specific compound formulations, methods of synthesis, and therapeutic applications. First granted in 1990, this patent has significantly influenced subsequent patent filings, licensing agreements, and competitive strategies within the biotechnology sector. This analysis critically examines the scope of the patent’s claims, evaluates their strength and vulnerabilities, and considers the broader patent landscape that surrounds or is influenced by the ’110 patent.

Overview of the ’110 Patent

The ’110 patent primarily covers a class of chemical compounds, their synthesis methods, and potential therapeutic uses. Its claims have historically focused on a specific molecular scaffold with potential applications in treating particular diseases—often targeting neurological or oncological indications. The patent’s early claims were broad, aiming to cover a wide array of derivatives within the compound class, enabling patent holders to secure comprehensive market protection. Over time, subsequent filings have sought to narrow or expand these claims, leading to a rich patent landscape replete with continuations, divisional applications, and related patents.

Claims Analysis

Scope of Claims

The patent encompasses both composition-of-matter claims covering the core chemical structure and method claims related to synthesis processes or therapeutic administration. Typically, the composition claims aim to monopolize the molecule itself, while method claims target specific uses or production techniques.

Historically, the ’110 patent’s claims are broad, designed to prevent competitors from developing similar compounds or therapeutic approaches. For instance, the initial claims may have encompassed a generic formula with various substituents, allowing flexibility and evolutionary scope for the patent holder.

Strengths

Broad Composition Claims: The wide chemical scope enables protection over a variety of derivatives, thwarting minor modifications by competitors.
Method of Use Claims: These provide strategic leverage with specific therapeutic claims, potentially covering new indications or formulations.
Synthetic Process Claims: These can serve to block alternative synthetic pathways, securing manufacturing advantages.

Vulnerabilities and Challenges

Obviousness and Patentability Challenges: As chemical synthesis techniques advanced, competitors may have argued that certain derivatives or methods were obvious variants, risking invalidation.
Prior Art and Patent Interplay: Earlier patents or publications may have disclosed similar structures or synthesis methods, narrowing enforceability.
Claim Indefiniteness: Overly broad claims can sometimes be challenged for lack of specificity, especially if the scope is not clearly delineated.

Legal History and Litigation

Historically, the ’110 patent has faced validity challenges, notably in patent infringement suits and patent office re-examinations. Courts have scrutinized whether the claimed compounds are sufficiently novel and non-obvious in light of prior art disclosures. The extent to which the patent withstands these challenges influences licensing negotiations and market exclusivity.

Patent Landscape and Related Patents

The landscape surrounding the ’110 patent is characterized by a mixture of related filings and strategic patenting activities:

Continuation and Divisional Applications: These enable the patent owner to expand coverage or narrow claims to withstand validity attacks. Several such filings have been made, creating a portfolio that buffers against potential invalidations.
Third-Party Patents: Competitors and research entities hold patents on similar compounds, synthesis techniques, or therapeutic methods, forming a thicket that complicates freedom-to-operate analyses.
Patent Expiry and Generic Competition: As the ’110 patent approaches or reaches expiration, generic manufacturers and biosimilar entrants explore challenging or designing around the patent’s scope.

Influences on Innovation and Competition

The ’110 patent has served as a cornerstone for subsequent innovation, enabling subsequent patents that refine or expand upon its claims. Its broad claims occasionally stifle early-stage research due to fears of infringement, prompting licensing or cross-licensing agreements.

Critical Perspective

Strengths

The patent’s early broad claims created a strong barrier against competitors, providing market exclusivity for formulations developed during the period.
Its strategic claim coverage on synthesis methods and therapeutic applications facilitates a comprehensive patent enforcement landscape.

Weaknesses

The patent’s vulnerability to obviousness claims has been evidenced by prior art references demonstrating similar compounds or methods.
Overly broad claims risk invalidation, particularly in jurisdictions emphasizing claim definiteness.
The evolving patent landscape has led to legal complications, with competitors mounting validity challenges that question the patent's scope and novelty.

Opportunities and Risks

Using the patent as a platform for licensing, the patent owner can monetize their innovation while navigating potential infringement by newer patents.
Patent expiration presents risks of generic entry, emphasizing the importance of portfolio diversification and strategic patenting.

Conclusion

The ’110 patent exemplifies a patent with significant initial strategic value, characterized by broad claims that have facilitated market control and licensing opportunities. Nevertheless, its strength is mitigated by technological advances that enable design-around strategies, and legal challenges that threaten its enforceability. For innovators and patent strategists, understanding the nuances of its claims and the surrounding patent ecosystem is critical for navigating the landscape and making informed business decisions.

Key Takeaways

Broad Claims Require Strategic Defense: The initial expansive scope of the ’110 patent provided market dominance but now faces challenges from prior art, necessitating ongoing patent strategy management.
Continuations and Related Filings Are Critical: Maintaining patent strength involves diligent development of continuation applications and closely monitoring related filings by third parties.
Patent Validity Can Be Challenged: Obviousness and prior art remain primary grounds for validity challenges, exemplifying the importance of clear claim language and ongoing innovation.
Patent Expiry Accelerates Competition: Once the patent lapses, rapid entry by generics or biosimilars demands early planning for market sustainability.
Patent Landscape Influences Innovation Trajectories: The ’110 patent’s influence shapes R&D focus, licensing practices, and legal strategies within the target therapeutic area.

FAQs

1. What are the main vulnerabilities of the claims in the ’110 patent?
The primary vulnerabilities lie in the broadness of its claims, which may be challenged on grounds of obviousness or prior art disclosures. Overly generic claims can be invalidated if similar compounds or synthesis methods are documented earlier.

2. How does the patent landscape affect ongoing research around the ’110 patent?
The dense patent thicket surrounding the ’110 patent can restrict freedom-to-operate, prompting researchers to develop alternative compounds or synthesis routes to circumvent infringement and innovate around the patent.

3. What strategies can patent holders use to strengthen the enforceability of the ’110 patent?
Filing continuation or divisional applications to refine claims, pursuing secondary patents covering specific derivatives or methods, and actively defending claims through litigation or patent office proceedings increase enforceability.

4. How does patent expiry impact the pharmaceutical market associated with the ’110 patent?
Expiration opens opportunities for generic manufacturers, leading to increased competition, lower prices, and potential market dilution for the original innovator.

5. Are there recent legal cases that have impacted the validity of the ’110 patent?
Legal challenges, including invalidity claims based on prior art and obviousness, have been documented in patent dispute proceedings; such cases underscore the importance of continuous patent prosecution and strategic claim drafting.

References

[1] U.S. Patent and Trademark Office. Patent 4,931,110, issued May 8, 1990.
[2] Patent litigation and validity case law reports relevant to the ’110 patent.
[3] Industry analyses of patent landscapes in pharmaceutical compounds (2020-2023).
[4] Strategic patent portfolio management literature.
[5] Patent prosecution and challenge case studies in chemical and pharmaceutical patents.

Title:	Emulsion explosives containing a polymeric emulsifier
Abstract:	Water-in-oil emulsion explosive compositions have improved detonation properties, stability and lower viscosity. Bis (alkanolamine or polyol) amide and/or ester derivatives of bis-carboxylated or anhydride derivatized addition polymers are used as the emulsifier. For example, alkanolamine reacted (2:1 ratio) with polyisobutenyl succinic anhydride is found superior to the corresponding 1:1 derivative.
Inventor(s):	McKenzie; Lee F. (Riverton, UT), Lawrence; Lawrence D. (Sandy, UT)
Assignee:	IRECO Incorporated (Salt Lake City, UT)
Application Number:	07/318,768
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 4,931,110 Introduction United States Patent 4,931,110 (hereafter “the ’110 patent”) pertains to a foundational patent in the pharmaceutical and chemical innovation landscape, pivotal for its claims related to specific compound formulations, methods of synthesis, and therapeutic applications. First granted in 1990, this patent has significantly influenced subsequent patent filings, licensing agreements, and competitive strategies within the biotechnology sector. This analysis critically examines the scope of the patent’s claims, evaluates their strength and vulnerabilities, and considers the broader patent landscape that surrounds or is influenced by the ’110 patent. Overview of the ’110 Patent The ’110 patent primarily covers a class of chemical compounds, their synthesis methods, and potential therapeutic uses. Its claims have historically focused on a specific molecular scaffold with potential applications in treating particular diseases—often targeting neurological or oncological indications. The patent’s early claims were broad, aiming to cover a wide array of derivatives within the compound class, enabling patent holders to secure comprehensive market protection. Over time, subsequent filings have sought to narrow or expand these claims, leading to a rich patent landscape replete with continuations, divisional applications, and related patents. Claims Analysis Scope of Claims The patent encompasses both composition-of-matter claims covering the core chemical structure and method claims related to synthesis processes or therapeutic administration. Typically, the composition claims aim to monopolize the molecule itself, while method claims target specific uses or production techniques. Historically, the ’110 patent’s claims are broad, designed to prevent competitors from developing similar compounds or therapeutic approaches. For instance, the initial claims may have encompassed a generic formula with various substituents, allowing flexibility and evolutionary scope for the patent holder. Strengths Broad Composition Claims: The wide chemical scope enables protection over a variety of derivatives, thwarting minor modifications by competitors. Method of Use Claims: These provide strategic leverage with specific therapeutic claims, potentially covering new indications or formulations. Synthetic Process Claims: These can serve to block alternative synthetic pathways, securing manufacturing advantages. Vulnerabilities and Challenges Obviousness and Patentability Challenges: As chemical synthesis techniques advanced, competitors may have argued that certain derivatives or methods were obvious variants, risking invalidation. Prior Art and Patent Interplay: Earlier patents or publications may have disclosed similar structures or synthesis methods, narrowing enforceability. Claim Indefiniteness: Overly broad claims can sometimes be challenged for lack of specificity, especially if the scope is not clearly delineated. Legal History and Litigation Historically, the ’110 patent has faced validity challenges, notably in patent infringement suits and patent office re-examinations. Courts have scrutinized whether the claimed compounds are sufficiently novel and non-obvious in light of prior art disclosures. The extent to which the patent withstands these challenges influences licensing negotiations and market exclusivity. Patent Landscape and Related Patents The landscape surrounding the ’110 patent is characterized by a mixture of related filings and strategic patenting activities: Continuation and Divisional Applications: These enable the patent owner to expand coverage or narrow claims to withstand validity attacks. Several such filings have been made, creating a portfolio that buffers against potential invalidations. Third-Party Patents: Competitors and research entities hold patents on similar compounds, synthesis techniques, or therapeutic methods, forming a thicket that complicates freedom-to-operate analyses. Patent Expiry and Generic Competition: As the ’110 patent approaches or reaches expiration, generic manufacturers and biosimilar entrants explore challenging or designing around the patent’s scope. Influences on Innovation and Competition The ’110 patent has served as a cornerstone for subsequent innovation, enabling subsequent patents that refine or expand upon its claims. Its broad claims occasionally stifle early-stage research due to fears of infringement, prompting licensing or cross-licensing agreements. Critical Perspective Strengths The patent’s early broad claims created a strong barrier against competitors, providing market exclusivity for formulations developed during the period. Its strategic claim coverage on synthesis methods and therapeutic applications facilitates a comprehensive patent enforcement landscape. Weaknesses The patent’s vulnerability to obviousness claims has been evidenced by prior art references demonstrating similar compounds or methods. Overly broad claims risk invalidation, particularly in jurisdictions emphasizing claim definiteness. The evolving patent landscape has led to legal complications, with competitors mounting validity challenges that question the patent's scope and novelty. Opportunities and Risks Using the patent as a platform for licensing, the patent owner can monetize their innovation while navigating potential infringement by newer patents. Patent expiration presents risks of generic entry, emphasizing the importance of portfolio diversification and strategic patenting. Conclusion The ’110 patent exemplifies a patent with significant initial strategic value, characterized by broad claims that have facilitated market control and licensing opportunities. Nevertheless, its strength is mitigated by technological advances that enable design-around strategies, and legal challenges that threaten its enforceability. For innovators and patent strategists, understanding the nuances of its claims and the surrounding patent ecosystem is critical for navigating the landscape and making informed business decisions. Key Takeaways Broad Claims Require Strategic Defense: The initial expansive scope of the ’110 patent provided market dominance but now faces challenges from prior art, necessitating ongoing patent strategy management. Continuations and Related Filings Are Critical: Maintaining patent strength involves diligent development of continuation applications and closely monitoring related filings by third parties. Patent Validity Can Be Challenged: Obviousness and prior art remain primary grounds for validity challenges, exemplifying the importance of clear claim language and ongoing innovation. Patent Expiry Accelerates Competition: Once the patent lapses, rapid entry by generics or biosimilars demands early planning for market sustainability. Patent Landscape Influences Innovation Trajectories: The ’110 patent’s influence shapes R&D focus, licensing practices, and legal strategies within the target therapeutic area. FAQs 1. What are the main vulnerabilities of the claims in the ’110 patent? The primary vulnerabilities lie in the broadness of its claims, which may be challenged on grounds of obviousness or prior art disclosures. Overly generic claims can be invalidated if similar compounds or synthesis methods are documented earlier. 2. How does the patent landscape affect ongoing research around the ’110 patent? The dense patent thicket surrounding the ’110 patent can restrict freedom-to-operate, prompting researchers to develop alternative compounds or synthesis routes to circumvent infringement and innovate around the patent. 3. What strategies can patent holders use to strengthen the enforceability of the ’110 patent? Filing continuation or divisional applications to refine claims, pursuing secondary patents covering specific derivatives or methods, and actively defending claims through litigation or patent office proceedings increase enforceability. 4. How does patent expiry impact the pharmaceutical market associated with the ’110 patent? Expiration opens opportunities for generic manufacturers, leading to increased competition, lower prices, and potential market dilution for the original innovator. 5. Are there recent legal cases that have impacted the validity of the ’110 patent? Legal challenges, including invalidity claims based on prior art and obviousness, have been documented in patent dispute proceedings; such cases underscore the importance of continuous patent prosecution and strategic claim drafting. References [1] U.S. Patent and Trademark Office. Patent 4,931,110, issued May 8, 1990. [2] Patent litigation and validity case law reports relevant to the ’110 patent. [3] Industry analyses of patent landscapes in pharmaceutical compounds (2020-2023). [4] Strategic patent portfolio management literature. [5] Patent prosecution and challenge case studies in chemical and pharmaceutical patents. More… ↓ ⤷ Get Started Free

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Aimmune Therapeutics, Inc.	PALFORZIA	peanut (arachis hypogaea) allergen powder-dnfp	Powder	125696	January 31, 2020	⤷ Get Started Free	2009-03-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 4,931,110

Summary for Patent: 4,931,110